Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2024-11-12 00:00:00 ET · period of report 2024-11-08 · accession 0000914475-24-000220 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-11-12 | 2024-11-08 | NBIX | ROBERTS EIRY | Chief Medical Off | M - OptEx | $81.67 | +7,345 | 30.1K | +32% | +$599.9K |
| DM | 2024-11-12 | 2024-11-08 | NBIX | ROBERTS EIRY | Chief Medical Off | M - OptEx | $0.00 | -7,345 | 1,265 | -85% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-08 | M | A | 1 | $79.02 | 31,061 | D | — | — | (F2) 29,876 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power. |
| 2 | Common | Common Stock | 2024-11-08 | M | A | 971 | $102.90 | 31,060 | D | — | — | |
| 3 | Common | Common Stock | 2024-11-08 | M | A | 5,140 | $77.81 | 28,856 | D | — | — | |
| 4 | Common | Common Stock | 2024-11-08 | M | A | 1,233 | $81.05 | 30,089 | D | — | — | |
| 5 | Derivative | Incentive Stock Option | 2024-11-08 | M | D | 5,140 | $0.00 | 0 | D | $77.81 · — to 2028-01-08 | 5,140 Common Stock | (F3) Represents option of which 1/4th of the shares underlying the option became vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter. |
| 6 | Derivative | Incentive Stock Option | 2024-11-08 | M | D | 971 | $0.00 | 0 | D | $102.90 · — to 2030-02-06 | 971 Common Stock | (F5) Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter. |
| 7 | Derivative | Incentive Stock Option | 2024-11-08 | M | D | 1,233 | $0.00 | 0 | D | $81.05 · — to 2029-02-07 | 1,233 Common Stock | (F4) Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter. |
| 8 | Derivative | Incentive Stock Option | 2024-11-08 | M | D | 1 | $0.00 | 1,265 | D | $79.02 · — to 2032-01-31 | 1 Common Stock | (F6) Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. |